ALX ONCOLOGY HOLDINGS INC Cash and Cash Equivalents
ALX ONCOLOGY HOLDINGS INC (ALXO) had Cash and Cash Equivalents of $22.69 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Assets › Assets, Current › Cash, Cash Equivalents, and Short-Term Investments › Cash and Cash Equivalent
us-gaap:CashAndCashEquivalentsAtCarryingValue · last filed 2026-08-06
- 2026-06-30: Cash and Cash Equivalents, at Carrying Value $22.69M.
- 2026-03-31: Cash and Cash Equivalents, at Carrying Value $32.28M.
- 2025-12-31: Cash and Cash Equivalents, at Carrying Value $16.37M.
- 2025-09-30: Cash and Cash Equivalents, at Carrying Value $23.44M.
| Period end | Cash and Cash Equivalents, at Carrying Value |
|---|---|
| 2026-06-30 | $22.69M 10-Q · filed 2026-08-06 |
| 2026-03-31 | $32.28M 10-Q · filed 2026-05-08 |
| 2025-12-31 | $16.37M 10-Q · filed 2026-08-06 |
| 2025-09-30 | $23.44M 10-Q · filed 2025-11-07 |
| 2025-06-30 | $19.30M 10-Q · filed 2026-08-06 |
| 2025-03-31 | $20.61M 10-Q · filed 2026-05-08 |
| 2024-12-31 | $17.57M 10-K · filed 2026-03-09 |
| 2024-09-30 | $16.10M 10-Q · filed 2025-11-07 |
| 2024-06-30 | $15.53M 10-Q · filed 2025-08-12 |
| 2024-03-31 | $14.04M 10-Q · filed 2025-05-08 |
| 2023-12-31 | $22.41M 10-K · filed 2026-03-09 |
| 2023-09-30 | $19.58M 10-Q · filed 2024-11-07 |
| 2023-06-30 | $38.04M 10-Q · filed 2024-08-12 |
| 2023-03-31 | $63.19M 10-Q · filed 2024-05-09 |
| 2022-12-31 | $48.82M 10-K · filed 2025-03-06 |
| 2022-09-30 | $49.05M 10-Q · filed 2023-11-13 |
| 2022-06-30 | $66.38M 10-Q · filed 2023-08-10 |
| 2022-03-31 | $159.09M 10-Q · filed 2023-05-11 |
| 2021-12-31 | $363.67M 10-K · filed 2024-03-07 |
| 2021-09-30 | $385.15M 10-Q · filed 2022-11-08 |
| 2021-06-30 | $409.96M 10-Q · filed 2022-08-08 |
| 2021-03-31 | $429.86M 10-Q · filed 2022-05-09 |
| 2020-12-31 | $434.22M 10-K · filed 2023-03-09 |
| 2020-09-30 | $259.48M 10-Q · filed 2020-11-12 |
| 2020-06-30 | $98.10M 10-Q · filed 2020-08-27 |
| 2019-12-31 | $9.02M 10-K · filed 2021-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 |